Related Experiment Video
Updated: Apr 27, 2026
10:21
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
914
CRR9p polymorphism as a protective factor for lung cancer
Summary
This meta-analysis found that the CRR9p polymorphism offers a protective effect against lung cancer (LC) risk. Evidence suggests this genetic variation may reduce the risk of developing lung cancer in both Caucasian and Asian populations.
Area of Science:
- Genetics
- Oncology
- Epidemiology
Background:
- The association between CRR9p polymorphism and lung cancer (LC) risk is inconsistent across studies.
- The precise role of CRR9p in LC pathogenesis requires further clarification.
Purpose of the Study:
- To conduct a meta-analysis to clarify the association between CRR9p polymorphism and lung cancer risk.
- To investigate the potential protective role of CRR9p in lung cancer development.
Main Methods:
- Searched PubMed, Embase, and Web of Science for relevant medical literature up to January 2014.
- Included eight studies in the meta-analysis.
- Utilized a fixed-effects model to calculate pooled odds ratios (ORs) and 95% confidence intervals (CIs).
Main Results:
- A statistically significant protective effect of CRR9p polymorphism on overall LC risk was observed (e.g., TT vs. CC: OR=0.78, 95% CI=0.70-0.87).
- Both Caucasian and Asian populations showed a reduced risk of lung cancer associated with this polymorphism.
- Similar protective associations were found for non-small cell lung cancer (NSCLC) risk, with most genetic models showing significant results.
Conclusions:
- The CRR9p polymorphism demonstrates a protective effect against lung cancer, including NSCLC.
- This meta-analysis provides supportive evidence for the influence of CRR9p polymorphism on lung cancer risk.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
157
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157
02:59Cancer Prevention
6.5K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.5K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
01:05Single Nucleotide Polymorphisms-SNPs
14.4K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.4K
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
189
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
189
01:33Pleiotropy
31.2K
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
31.2K